Anticoagulation with nadroparin in continuous venovenous hemofiltration (CVVH): extracorporeal clearance and systemic effects of nadropari
Not yet recruiting
- Conditions
- acute renal failure(anti)stollingrenal replacement therapy10038430
- Registration Number
- NL-OMON29873
- Lead Sponsor
- Onze Lieve Vrouwe Gasthuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 30
Inclusion Criteria
non-surgical patients in the ICU with indication of CVVH for acute renal failure
Exclusion Criteria
severe liver failure
active bleeding and need for transfusion
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>· anti-Xa activity in plasma and ultrafiltrate<br /><br>· sieving coefficient of anti-Xa<br /><br>· clearance of anti-Xa in relation to CVVH dose</p><br>
- Secondary Outcome Measures
Name Time Method <p>The course of anti-Xa and ETP in plasma<br /><br>Relation between anti-Xa and ETP in plasma</p><br>